<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411836</url>
  </required_header>
  <id_info>
    <org_study_id>EFFORT</org_study_id>
    <nct_id>NCT04411836</nct_id>
  </id_info>
  <brief_title>Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine</brief_title>
  <acronym>EFFORT</acronym>
  <official_title>Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine - a Randomized Controlled Trial in P. Vivax Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Centre for Parasitology, Entomology and Malaria Control, Cambodia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ethiopian Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitas Sumatera Utara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Health care facility based, randomized, controlled, open label, superiority trial with 3 arms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To assess the effectiveness of a short-course of high dose primaquine (total dose 7mg/kg
           given unsupervised over 7 days) compared to the current standard low dose primaquine
           regimen (total dose 3.5mg/kg given unsupervised over 14 days).

        -  To assess the effectiveness of tafenoquine (single dose of 300mg) compared to the
           short-course high dose primaquine regimen.

        -  To assess the safety of tafenoquine compared to the high and low dose primaquine
           regimens.

        -  To assess the cost-effectiveness and feasibility of high dose primaquine and tafenoquine
           compared to the current low dose primaquine regimen
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence risk symptomatic P vivax PQ7 / PQ14</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6-month follow up period as determined by microscopy compared between the PQ7 arm and the control arm (PQ14).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence risk symptomatic P vivax PQ7 / TQ</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ7 and TQ arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk symptomatic P vivax TQ / PQ14</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between TQ and the control arm (PQ14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk any P vivax PQ7 / PQ14</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of any P. vivax parasitaemia during the 6-month follow up period as determined by microscopy compared between the PQ7 arm and the control arm (PQ14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk any P vivax PQ7 / TQ</measure>
    <time_frame>6 months</time_frame>
    <description>• The incidence risk (time to first event) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ7 and TQ arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence risk any P vivax PQ14 / TQ</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence risk (time to first event) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy compared between PQ14 and TQ arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Vivax Malaria</condition>
  <condition>Plasmodium Vivax</condition>
  <condition>Malaria, Vivax</condition>
  <condition>Malaria Relapse</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PQ Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQ Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafenoquine</intervention_name>
    <description>patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).</description>
    <arm_group_label>TQ Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)</description>
    <arm_group_label>PQ Intervention</arm_group_label>
    <other_name>Primaquine 7 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  P. vivax peripheral parasitaemia (mono-infection) as determined by microscopy

          -  G6PD normal status (G6PD activity ≥ 70% of the adjusted male median as determined by
             the Biosensor™ (SD Bioline, ROK))

          -  Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours

          -  Age ≥18 years

          -  Written informed consent

          -  Living in the study area and willing to be followed for six months

        Exclusion Criteria:

          -  Danger signs or symptoms of severe malaria

          -  Anaemia (defined as Hb &lt;8g/dl)

          -  Pregnant or lactating females

          -  Known hypersensitivity to any of the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Weston</last_name>
    <phone>0889468521</phone>
    <email>sophie.weston@menzies.edu.au</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tafenoquine</keyword>
  <keyword>primaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Tafenoquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

